Trial Reveals Safer And Simpler Approach To Treating Children With Cystic Fibrosis
Treating chest infections in young cystic fibrosis patients with an antibiotic once instead of three times daily is as effective and less toxic, conclude the results of a randomised trial published in this week’s issue of THE LANCET.
Aminoglycoside antibiotics are widely used for the management of patients who have cystic fibrosis and chronic chest infection with a bacterium called Pseudomonas aerginosa. Currently patients are given aminoglycosides three times daily. The drugs can cause damage to kidney function and hearing loss.
Alan Smyth (University of Nottingham, UK) and colleagues recruited 219 cystic fibrosis patients (125 children and 94 adults) between 1999 and 2003 in the UK. The patients were randomly assigned to receive an aminoglycoside called tobramycin intravenously once or three times daily for 14 days. The researchers measured changes in lung function and found that the two treatments had a similar effect. However in children, the once daily treatment caused fewer kidney related side effects.
Dr Alan Smyth comments: “Our results are likely to affect aminoglycoside prescription in cystic fibrosis in clinical practice. Once daily treatment may be preferred by patients receiving intravenous antibiotics because of its convenience. Antipseudomonal antibiotics are usually given as combinations of two or more drugs in cystic fibrosis because of concerns of emerging antibiotic resistance. Most other antipseudomonal antibiotics need to be given three times daily and so further development of other once daily antibiotics would be useful.”
In an accompanying commentary Heather VandenBussche (Bronson Methodist Hospital, Michigan, USA) and Michael Klepser (Ferris State University College of Pharmacy, Michigan, USA) write that several unanswered questions persist about once daily aminoglycoside dosing in cystic fibrosis patients.
Dr VandenBussche concludes: “ Smyth and colleagues’ report provides some useful insights into the safety and efficacy of once-daily administration of aminoglycosides in patients with cystic fibrosis. However, we need larger and longer studies that include adequate numbers of children and adults. Future studies should evaluate pharmokinetic variables and organism susceptibilities after multiple courses of tobramycin. Such studies would better address concerns about once-daily dosing and its effects on bacterial resistance in patients with cystic fibrosis
Udani Samarasekera | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...